3-hydroxybutyric acidWhat was measured
Measured, with no finding
535 endpoints
Show what was measuredHide what was measured
average 150-kJ time-trial power output
decreases, p = 0.029
Average time-trial power output was ∼7% lower (-16 W, p = 0.029) in the ketone condition
PMID 28750585 · one of two readings recorded this
average power output in a 150-kJ cycling time-trial
decreases, about 7% lower (-16 W), p = 0.029
Not recorded as a finding: endpoint_near_miss: mean-power-output requires a fixed-duration maximal effort and time-trial-performance requires fixed-distance completion time, while this is power over fixed work
Average time-trial power output was ∼7% lower (-16 W, p = 0.029) in the ketone condition.
PMID 28750585 · one of two readings recorded this
average power output over a 150-kJ cycling time-trial
decreases, about 7% lower (-16 W), p = 0.029
Not recorded as a finding: No node fits: time-trial-performance is a fixed-distance completion time and mean-power-output is a fixed-duration Wingate-type effort; this is mean power over a fixed-work trial
Average time-trial power output was ∼7% lower (-16 W, p = 0.029) in the ketone condition.
PMID 28750585 · one of two readings recorded this
plasma β-OHB
increases, p = 0.05
Plasma β-OHB was elevated from baseline and throughout the entire protocol in the ketone condition (p < 0.05)
PMID 28750585 · one of two readings recorded this
respiratory exchange ratio at 30% and 60% ventilatory threshold, indirect calorimetry
decreases
Not recorded as a finding: No outcome node for respiratory exchange ratio during exercise
RER was lower at 30% and 60% VT in the ketone compared with control condition.
PMID 28750585 · both readings recorded this
respiratory exchange ratio
decreases
RER was lower at 30% and 60% VT in the ketone compared with control condition
PMID 28750585 · one of two readings recorded this
respiratory exchange ratio
decreases
RER was lower at 30% and 60% VT in the ketone compared with control condition
PMID 28750585 · one of two readings recorded this
total fat oxidation
increases, p = 0.05
Total fat oxidation was greater in the ketone versus control (p = 0.05)
PMID 28750585 · one of two readings recorded this
total antioxidant capacity
increases, p = 0.028
Liver total antioxidant capacity levels were significantly higher in KD versus SC rats (p = 0.028), but not KD versus SC + KS rats (p = 0.216; Figure 8d)
PMID 28914762 · one of two readings recorded this
total antioxidant capacity
no effect, p = 0.275
was not different between the KD and SC groups (p = 0.275) or SC and SC + KS groups (p = 0.366)
PMID 28914762 · one of two readings recorded this
total antioxidant capacity
no effect, p = 0.366
was not different between the KD and SC groups (p = 0.275) or SC and SC + KS groups (p = 0.366)
PMID 28914762 · one of two readings recorded this
total antioxidant capacity
no effect, p = 0.216
Liver total antioxidant capacity levels were significantly higher in KD versus SC rats (p = 0.028), but not KD versus SC + KS rats (p = 0.216; Figure 8d)
PMID 28914762 · one of two readings recorded this
total antioxidant capacity
decreases, p = 0.019
gastrocnemius antioxidant capacity was significantly lower in KD versus SC + KS rats (p = 0.019)
PMID 28914762 · one of two readings recorded this
total antioxidant capacity
no effect, p = 0.146
Gastrocnemius total antioxidant capacity levels were not different between groups (ANOVA p = 0.146; Figure 8d)
PMID 28914762 · one of two readings recorded this
total antioxidant capacity
modulates, p = 0.025
Gastrocnemius antioxidant capacity was significantly different between groups (ANOVA p = 0.025; Figure 2d)
PMID 28914762 · one of two readings recorded this
4-HNE
no effect, p = 0.725
gastrocnemius 4-HNE (ANOVA p = 0.725) and protein carbonyl levels (ANOVA p = 0.504) were not differentially expressed groups
PMID 28914762 · one of two readings recorded this
change in body mass
decreases, p = 0.001
change in body mass at day 3 was significantly lower in KD versus SC and SC + KS rats (p < 0.001 and p < 0.001, respectively)
PMID 28914762 · one of two readings recorded this
change in body mass
decreases, p = 0.01
this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)
PMID 28914762 · one of two readings recorded this
change in body mass
decreases, p = 0.036
this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)
PMID 28914762 · one of two readings recorded this
change in body mass
decreases, p = 0.001
change in body mass at day 3 was significantly lower in KD versus SC and SC + KS rats (p < 0.001 and p < 0.001, respectively)
PMID 28914762 · one of two readings recorded this
change in body mass
decreases, p = 0.002
this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)
PMID 28914762 · one of two readings recorded this
change in body mass
decreases, p = 0.001
this difference persisted at day 5 (p = 0.010 and p = 0.002, respectively) and day 7 (p = 0.036 and p < 0.001, respectively)
PMID 28914762 · one of two readings recorded this
citrate synthase activity
no effect, p = 0.386
Citrate synthase activity levels in the brain (ANOVA p = 0.386) and liver (ANOVA p = 0.548) were similar between groups
PMID 28914762 · one of two readings recorded this
citrate synthase activity
decreases, p = 0.009
values were lower in KD versus SC + KS (p < 0.001) and SC (p = 0.009) rats
PMID 28914762 · one of two readings recorded this
citrate synthase activity
decreases, p = 0.001
values were lower in KD versus SC + KS (p < 0.001) and SC (p = 0.009) rats
PMID 28914762 · one of two readings recorded this
feed efficiency
decreases, p = 0.001
KD rats presented significantly feed efficiency values compared to SC + KS rats (p < 0.001) and SC rats (p < 0.001)
PMID 28914762 · one of two readings recorded this
feed efficiency
unclear, p = 0.07
KD rats presented significantly lower values compared to SC + KS rats (p < 0.001) and differences between KD and SC rats approached significance (p = 0.070)
PMID 28914762 · one of two readings recorded this
feed efficiency
decreases, p = 0.001
KD rats presented significantly feed efficiency values compared to SC + KS rats (p < 0.001) and SC rats (p < 0.001)
PMID 28914762 · one of two readings recorded this
feed efficiency
decreases, p = 0.001
KD rats presented significantly lower values compared to SC + KS rats (p < 0.001) and differences between KD and SC rats approached significance (p = 0.070)
PMID 28914762 · one of two readings recorded this
liver protein carbonyls by Oxyblot Western blot, Fisher 344 rats fed standard chow plus sodium DL-beta-hydroxybutyrate in drinking water for 8 months against standard chow alone
increases, protein carbonyls greater in SC + KS than in SC, p = 0.034, p = 0.034
Not recorded as a finding: this platform holds no node for the endpoint
Liver 4-HNE levels were not differentially expressed between groups (ANOVA p = 0.684), although liver protein carbonyls were greater in the SC + KS versus SC (p = 0.034) and KD (p = 0.001) groups.
PMID 28914762 · one of two readings recorded this
mitochondrial GSH
no effect, p = 0.191
Brain mitochondrial GSSG (ANOVA p = 0.294), GSH (ANOVA p = 0.191) and total glutathione (ANOVA p = 0.200) were not differentially expressed between groups
PMID 28914762 · one of two readings recorded this
mitochondrial GSH
increases, p = 0.001
GSH levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.004) groups
PMID 28914762 · one of two readings recorded this
mitochondrial GSH
increases, p = 0.004
GSH levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.004) groups
PMID 28914762 · one of two readings recorded this
mitochondrial GSSG
no effect, p = 0.294
Brain mitochondrial GSSG (ANOVA p = 0.294), GSH (ANOVA p = 0.191) and total glutathione (ANOVA p = 0.200) were not differentially expressed between groups
PMID 28914762 · one of two readings recorded this
mitochondrial GSSG
increases, p = 0.018
GSSG levels were greater in SC-fed versus KD-fed rats (p = 0.018) and trended higher in SC-fed versus SC + KS-fed rats (p = 0.063)
PMID 28914762 · one of two readings recorded this
mitochondrial GSSG
unclear, p = 0.063
GSSG levels were greater in SC-fed versus KD-fed rats (p = 0.018) and trended higher in SC-fed versus SC + KS-fed rats (p = 0.063)
PMID 28914762 · one of two readings recorded this
mitochondrial ROS production
no effect, p = 0.162
Mitochondrial ROS production in the brain (ANOVA p = 0.162) and liver (ANOVA p = 0.222) were not different between groups
PMID 28914762 · one of two readings recorded this
mitochondrial ROS production
increases, p = 0.014
ROS values were significantly higher in KD rats versus the SC (p = 0.014) and SC + KS groups (p = 0.015)
PMID 28914762 · one of two readings recorded this
mitochondrial ROS production
increases, p = 0.015
ROS values were significantly higher in KD rats versus the SC (p = 0.014) and SC + KS groups (p = 0.015)
PMID 28914762 · one of two readings recorded this
mitochondrial total glutathione
no effect, p = 0.2
Brain mitochondrial GSSG (ANOVA p = 0.294), GSH (ANOVA p = 0.191) and total glutathione (ANOVA p = 0.200) were not differentially expressed between groups
PMID 28914762 · one of two readings recorded this
mitochondrial total glutathione
increases, p = 0.001
total glutathione levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.005) groups
PMID 28914762 · one of two readings recorded this
mitochondrial total glutathione
increases, p = 0.005
total glutathione levels were greater in the SC versus the KD (p = 0.001) and SC + KS (p = 0.005) groups
PMID 28914762 · one of two readings recorded this
oxidative stress-related mRNAs (Gclm, Gclc, Gsr, Gpx1, Cat, Sod2)
no effect, p = 0.05
Oxidative stress-related genes (i.e., Gclm, Gclc, Gsr, Gpx1, Cat or Sod2) were not differentially expressed in the gastrocnemius, brain or liver (all ANOVA p > 0.05; Figure 2a–c)
PMID 28914762 · one of two readings recorded this
oxidative stress-related mRNAs (Gclm, Gclc, Gsr, Gpx1, Cat, Sod2)
no effect, p = 0.05
Oxidative stress-related genes (i.e., Gclm, Gclc, Gsr, Gpx1, Cat or Sod2) were not differentially expressed in the gastrocnemius, brain or liver (all ANOVA p > 0.05; Figure 2a–c)
PMID 28914762 · one of two readings recorded this
oxidative stress-related mRNAs (Gclm, Gclc, Gsr, Gpx1, Cat, Sod2)
no effect, p = 0.05
Oxidative stress-related genes (i.e., Gclm, Gclc, Gsr, Gpx1, Cat or Sod2) were not differentially expressed in the gastrocnemius, brain or liver (all ANOVA p > 0.05; Figure 2a–c)
PMID 28914762 · one of two readings recorded this
protein carbonyls
no effect, p = 0.504
gastrocnemius 4-HNE (ANOVA p = 0.725) and protein carbonyl levels (ANOVA p = 0.504) were not differentially expressed groups
PMID 28914762 · one of two readings recorded this
protein carbonyls
increases, p = 0.034
liver protein carbonyls were greater in the SC + KS versus SC (p = 0.034) and KD (p = 0.001) groups
PMID 28914762 · one of two readings recorded this
protein carbonyls
increases, p = 0.001
liver protein carbonyls were greater in the SC + KS versus SC (p = 0.034) and KD (p = 0.001) groups
PMID 28914762 · one of two readings recorded this
protein expression of Cat
no effect, p = 0.393
Gastrocnemius protein expression levels of Cat (ANOVA p = 0.393), Gpx (ANOVA p = 0.702) and Sod2 (ANOVA p = 0.925) were not differentially expressed between groups
PMID 28914762 · one of two readings recorded this
protein expression of Gpx
no effect, p = 0.702
Gastrocnemius protein expression levels of Cat (ANOVA p = 0.393), Gpx (ANOVA p = 0.702) and Sod2 (ANOVA p = 0.925) were not differentially expressed between groups
PMID 28914762 · one of two readings recorded this
protein expression of Gpx
increases, p = 0.004
Liver protein expression levels of Gpx were greater in the KD versus the SC group (p = 0.004) and high levels approached significance in the KD versus the SC + KS group (p = 0.068)
PMID 28914762 · one of two readings recorded this
protein expression of Gpx
unclear, p = 0.068
Liver protein expression levels of Gpx were greater in the KD versus the SC group (p = 0.004) and high levels approached significance in the KD versus the SC + KS group (p = 0.068)
PMID 28914762 · one of two readings recorded this
protein expression of Sod2
no effect, p = 0.925
Gastrocnemius protein expression levels of Cat (ANOVA p = 0.393), Gpx (ANOVA p = 0.702) and Sod2 (ANOVA p = 0.925) were not differentially expressed between groups
PMID 28914762 · one of two readings recorded this
pyruvate-malate respiratory control ratio
no effect, p = 0.582
Brain pyruvate-malate state 3 (ANOVA p = 0.706), pyruvate-malate state 4 (ANOVA p = 0.500) and pyruvate-malate RCR values (ANOVA p = 0.582; Figure 10a) were not different between groups
PMID 28914762 · one of two readings recorded this
pyruvate-malate respiratory control ratio
decreases, p = 0.03
values were significantly lower in KD versus SC rats (p = 0.030) and SC + KS versus SC rats (p = 0.035)
PMID 28914762 · one of two readings recorded this
pyruvate-malate respiratory control ratio
decreases, p = 0.035
values were significantly lower in KD versus SC rats (p = 0.030) and SC + KS versus SC rats (p = 0.035)
PMID 28914762 · one of two readings recorded this
pyruvate-malate state 3 respiration
no effect, p = 0.706
Brain pyruvate-malate state 3 (ANOVA p = 0.706), pyruvate-malate state 4 (ANOVA p = 0.500) and pyruvate-malate RCR values (ANOVA p = 0.582; Figure 10a) were not different between groups
PMID 28914762 · one of two readings recorded this
pyruvate-malate state 3 respiration
unclear, p = 0.064
lower values in KD versus SC rats approached significance (p = 0.064)
PMID 28914762 · one of two readings recorded this
pyruvate-malate state 4 respiration
no effect, p = 0.119
Gastrocnemius pyruvate-malate state 4 was not different between groups (p = 0.119; Figure 9b)
PMID 28914762 · one of two readings recorded this
rotarod performance, main group effect
increases, p = 0.001
rotarod performance was significantly higher in KD rats versus SC (p = 0.001) and SC + KS rats (p = 0.005)
PMID 28914762 · one of two readings recorded this
rotarod performance, main group effect
increases, p = 0.005
rotarod performance was significantly higher in KD rats versus SC (p = 0.001) and SC + KS rats (p = 0.005)
PMID 28914762 · one of two readings recorded this
rotarod performance over time within KD group
decreases, p = 0.006
within the KD group there was a significant time effect (p = 0.001) whereby values at 6 months (p = 0.006) and 8 months (p = 0.021) were significantly lower than 2 months values
PMID 28914762 · one of two readings recorded this
rotarod performance over time within KD group
decreases, p = 0.021
within the KD group there was a significant time effect (p = 0.001) whereby values at 6 months (p = 0.006) and 8 months (p = 0.021) were significantly lower than 2 months values
PMID 28914762 · one of two readings recorded this
rotarod performance over time within KD group
decreases, p = 0.001
within the KD group there was a significant time effect (p = 0.001) whereby values at 6 months (p = 0.006) and 8 months (p = 0.021) were significantly lower than 2 months values
PMID 28914762 · one of two readings recorded this
rotarod performance over time within SC group
no effect, p = 0.531
there was no time effect within the SC (p = 0.531) and SC + KS groups (p = 0.382)
PMID 28914762 · one of two readings recorded this
rotarod performance over time within SC + KS group
no effect, p = 0.382
there was no time effect within the SC (p = 0.531) and SC + KS groups (p = 0.382)
PMID 28914762 · one of two readings recorded this
rotarod performance
increases, p = 0.001
at 2 months, performance was significantly higher in the KD versus the SC (p < 0.001) and SC + KS groups (p = 0.009)
PMID 28914762 · one of two readings recorded this
rotarod performance
increases, p = 0.017
at 4 months, performance was significantly higher in the KD versus the SC (p = 0.017) group, and values between the KD versus SC + KS group approached significance (p = 0.060)
PMID 28914762 · one of two readings recorded this
rotarod performance
increases, p = 0.008
at 8 months, performance was significantly higher in the KD versus the SC (p = 0.008) and SC + KS groups (p = 0.049)
PMID 28914762 · one of two readings recorded this
rotarod performance
increases, p = 0.009
at 2 months, performance was significantly higher in the KD versus the SC (p < 0.001) and SC + KS groups (p = 0.009)
PMID 28914762 · one of two readings recorded this
rotarod performance
unclear, p = 0.06
at 4 months, performance was significantly higher in the KD versus the SC (p = 0.017) group, and values between the KD versus SC + KS group approached significance (p = 0.060)
PMID 28914762 · one of two readings recorded this
rotarod performance
increases, p = 0.049
at 8 months, performance was significantly higher in the KD versus the SC (p = 0.008) and SC + KS groups (p = 0.049)
PMID 28914762 · one of two readings recorded this
serum BHB
increases, p = 0.001
serum BHB values were higher in KD versus SC rats (p < 0.001) and SC + KS rats (p < 0.001)
PMID 28914762 · one of two readings recorded this
serum BHB
no effect, p = 0.14
serum BHB levels were higher in KD versus SC + KS rats (p = 0.034), but not different between KD and SC rats (p = 0.140)
PMID 28914762 · one of two readings recorded this
serum BHB
increases, p = 0.001
serum BHB values were higher in KD versus SC rats (p < 0.001) and SC + KS rats (p < 0.001)
PMID 28914762 · one of two readings recorded this
serum BHB
increases, p = 0.034
serum BHB levels were higher in KD versus SC + KS rats (p = 0.034), but not different between KD and SC rats (p = 0.140)
PMID 28914762 · one of two readings recorded this
sodium beta-hydroxybutyrate intake through drinking water
SC + KS rats consumed an average of 0.85 ± 0.03 g/day of sodium beta-hydroxybutyrate over the 1-week intervention through their drinking water
PMID 28914762 · one of two readings recorded this
sodium beta-hydroxybutyrate salt intake through drinking water
SC + KS rats consumed an average of 0.21 ± 0.02 g/day of sodium beta-hydroxybutyrate salts through their drinking water over the 8 months intervention
PMID 28914762 · one of two readings recorded this
succinate respiratory control ratio
no effect, p = 0.582
Gastrocnemius succinate state 3 (ANOVA p = 0.706; Figure 9d), succinate state 4 (ANOVA p = 0.500; Figure 9e) and succinate RCR values (ANOVA p = 0.582; Figure 9f) were not different between groups
PMID 28914762 · one of two readings recorded this
succinate state 3 respiration
no effect, p = 0.706
Gastrocnemius succinate state 3 (ANOVA p = 0.706; Figure 9d), succinate state 4 (ANOVA p = 0.500; Figure 9e) and succinate RCR values (ANOVA p = 0.582; Figure 9f) were not different between groups
PMID 28914762 · one of two readings recorded this
succinate state 4 respiration
no effect, p = 0.5
Gastrocnemius succinate state 3 (ANOVA p = 0.706; Figure 9d), succinate state 4 (ANOVA p = 0.500; Figure 9e) and succinate RCR values (ANOVA p = 0.582; Figure 9f) were not different between groups
PMID 28914762 · one of two readings recorded this
weekly body mass
decreases, p = 0.05
KD rats weighed less than SC and SC + KS rats from 10 weeks to 30 weeks (p < 0.05 at all time points; Figure 3a)
PMID 28914762 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.0001
compared to both control (p < 0.0001 for KD, KS and KE) and baseline (p < 0.0001 for KD and KS; p = 0.03 for KE
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.0001
compared to both control (p < 0.0001 for both KE and KS) and baseline (p < 0.0001 for both KE and KS) levels
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.02
Significantly increased blood βHB levels were also detected in KE and KS supplemented mice, compared to their baseline levels (KE: p = 0.02; KS: p = 0.04)
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.03
compared to both control (p < 0.0001 for KD, KS and KE) and baseline (p < 0.0001 for KD and KS; p = 0.03 for KE
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.04
Significantly increased blood βHB levels were also detected in KE and KS supplemented mice, compared to their baseline levels (KE: p = 0.02; KS: p = 0.04)
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0001
compared to both control (p < 0.0001 for KD, KS and KE) and baseline (p < 0.0001 for KD and KS; p = 0.03 for KE
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
unclear, p = 0.07
The mice fed KD, or SD with KE, or KS exhibited elevated (KD: p = 0.07) or significantly increased (KE: p = 0.0117; KS: p = 0.0169) blood levels of βHB relative to control mice
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0001
compared to both control (p < 0.0001 for both KE and KS) and baseline (p < 0.0001 for both KE and KS) levels
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0117
The mice fed KD, or SD with KE, or KS exhibited elevated (KD: p = 0.07) or significantly increased (KE: p = 0.0117; KS: p = 0.0169) blood levels of βHB relative to control mice
PMID 30021521 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0169
The mice fed KD, or SD with KE, or KS exhibited elevated (KD: p = 0.07) or significantly increased (KE: p = 0.0117; KS: p = 0.0169) blood levels of βHB relative to control mice
PMID 30021521 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases, p = 0.27
when the group means were considered (R2 = 0.4531, p = 0.27)
PMID 30021521 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases, p = 0.096
positively correlated, but not significantly when the group means were considered (R2 = 0.8164, p = 0.096)
PMID 30021521 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases, p = 0.0001
when individual data points (R2 = 0.4481, p < 0.0001, Fig. 1c)
PMID 30021521 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases, p = 0.04
or the group means were considered (R2 = 0.995, p = 0.04)
PMID 30021521 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases, p = 0.0002
when individual data points (R2 = 0.4862, p = 0.0002, Fig. 3c)
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility, seconds from chamber closure, in Sprague-Dawley rats, G1D mice and WAG/Rij rats
increases
Not recorded as a finding: no outcome node for anaesthetic induction latency
Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively), relative to control mice fed a SD.
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility (time until immobility after chamber closure) in rats and G1D mice
increases
Not recorded as a finding: no outcome node for anaesthetic induction latency
Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively), relative to control mice fed a SD.
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.0003
Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively)
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.0001
Treatment with KD and SD with KS caused a significant increase in the number of seconds required before anesthetic induction (the time until immobility) (p < 0.0001, and p = 0.0337, respectively)
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.0003
Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively)
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.0001
SD with KE or KS significantly increased the time required before anesthetic induction (p < 0.0001, p = 0.02, respectively), compared to controls (SD) in WAG/Rij rats
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.0136
Chronic administration of KD, SD with KE, and SD with KS resulted in a significant increase in the time required for anesthetic induction (p = 0.0003, p = 0.0003, p = 0.0136, respectively)
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.0337
Treatment with KD and SD with KS caused a significant increase in the number of seconds required before anesthetic induction (the time until immobility) (p < 0.0001, and p = 0.0337, respectively)
PMID 30021521 · one of two readings recorded this
latency to isoflurane-induced immobility
increases, p = 0.02
SD with KE or KS significantly increased the time required before anesthetic induction (p < 0.0001, p = 0.02, respectively), compared to controls (SD) in WAG/Rij rats
PMID 30021521 · one of two readings recorded this
blood acetoacetate fold versus control
increases
In groups treated with KE, KE+MCT and KE/2 the AcAc levels were higher than control (water) by factors of 16, 15, and 14, respectively
PMID 30604923 · one of two readings recorded this
blood acetoacetate fold versus control
increases
In groups treated with KE, KE+MCT and KE/2 the AcAc levels were higher than control (water) by factors of 16, 15, and 14, respectively
PMID 30604923 · one of two readings recorded this
blood acetoacetate fold versus control
increases
In groups treated with KE, KE+MCT and KE/2 the AcAc levels were higher than control (water) by factors of 16, 15, and 14, respectively
PMID 30604923 · one of two readings recorded this
blood acetoacetate
increases, p = 0.0001
AcAc was significantly higher in all treatment groups compared to control (P < 0.0001; Fig. 3C)
PMID 30604923 · one of two readings recorded this
blood D-beta-hydroxybutyrate after gavage, Precision Xtra meter (does not detect L-beta-hydroxybutyrate), measured immediately after removal from the hyperbaric chamber; and latency to CNS oxygen toxicity seizure at 5 ATA
increases, about two times higher blood D-beta-hydroxybutyrate than control in the KS+MCT group, p = 0.0006
Not recorded as a finding: the intervention held more than the compound
The KE/2 group (P = 0.0012) had higher βHB level then the control by a factor of approximately three, while it was about two times higher in the KS+MCT (P = 0.0006) group.
PMID 30604923 · one of two readings recorded this
blood D-beta-hydroxybutyrate
increases, p = 0.0012
The KE/2 group (P = 0.0012) had higher βHB level then the control by a factor of approximately three
PMID 30604923 · one of two readings recorded this
blood D-beta-hydroxybutyrate
increases, p = 0.0002
Treatment with KE (P < 0.0001) and KE+MCT (P = 0.0002) resulted in higher βHB levels
PMID 30604923 · one of two readings recorded this
blood D-beta-hydroxybutyrate
increases, p = 0.0001
Treatment with KE (P < 0.0001) and KE+MCT (P = 0.0002) resulted in higher βHB levels
PMID 30604923 · one of two readings recorded this
blood D-beta-hydroxybutyrate
increases, p = 0.0006
while it was about two times higher in the KS+MCT (P = 0.0006) group
PMID 30604923 · one of two readings recorded this
blood glucose
no effect
Blood glucose and body weight were not significantly different between the treatment groups and control
PMID 30604923 · one of two readings recorded this
body weight
no effect
Blood glucose and body weight were not significantly different between the treatment groups and control
PMID 30604923 · one of two readings recorded this
correlation of blood D-beta-hydroxybutyrate with latency to seizure
increases
There was a strong positive correlation between βHB levels and LS when all treatment groups were considered
PMID 30604923 · one of two readings recorded this
delay to seizure relative to control
increases
The KE/2 group delayed seizure by 55%
PMID 30604923 · one of two readings recorded this
delay to seizure relative to control
increases
LS = 219%
PMID 30604923 · one of two readings recorded this
delay to seizure relative to control
increases
the KE group experienced a delay to seizure of 179%, as compared to the control group
PMID 30604923 · one of two readings recorded this
latency to seizure at 5 ATA
increases, p = 0.023
LS was significantly delayed in the KE (P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028) groups
PMID 30604923 · one of two readings recorded this
latency to seizure at 5 ATA
increases, p = 0.049
was documented in KE+MCT group (P = 0.049; Fig. 1A)
PMID 30604923 · one of two readings recorded this
latency to seizure at 5 ATA
increases, p = 0.028
LS was significantly delayed in the KE (P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028) groups
PMID 30604923 · one of two readings recorded this
latency to seizure at 5 ATA
increases, p = 0.0003
LS was significantly delayed in the KE (P = 0.0003), KE/2 (P = 0.023), and KE+MCT (P = 0.028) groups
PMID 30604923 · one of two readings recorded this
latency to seizure at 5 ATA
unclear
The KS+MCT treatment group showed a trend for delayed
PMID 30604923 · one of two readings recorded this
latency to seizure in young versus aged rats
no effect, p = 0.07
The LS in young and aged rats was not significantly different (P = 0.07)
PMID 30604923 · one of two readings recorded this
latency to seizure, KE versus KE/2
increases, p = 0.011
LS was also significantly different between KE and KE/2 groups (P = 0.011)
PMID 30604923 · one of two readings recorded this
latency to tonic-clonic seizure under hyperbaric oxygen at 5 ATA, and seizure severity score 0 to 3, 18-month-old Sprague-Dawley rats
no effect, KS+MCT showed a trend for delayed seizure latency, not significant against water control, n = 7
Not recorded as a finding: the intervention held more than the compound
The KS+MCT treatment group showed a trend for delayed CNS‐OT, but was not significant when compared to control (water).
PMID 30604923 · one of two readings recorded this
seizure severity score
unclear
showed a trend towards less severity without significance in KE/2, and KE+MCT groups
PMID 30604923 · one of two readings recorded this
seizure severity score
unclear
showed a trend towards less severity without significance in KE/2, and KE+MCT groups
PMID 30604923 · one of two readings recorded this
seizure severity score
decreases, p = 0.015
the severity of seizures, determined by the blinded experimenter, was significantly less in KE (P = 0.015)
PMID 30604923 · one of two readings recorded this
caspase-1 activation in LPS-stimulated whole blood, 30 min after dosing
increases, p = 0.012
Not recorded as a finding: no outcome node for stimulated caspase-1 activation; recorded in mechanism_claims
Caspase-1 activation increases after ketone salt (Study 1: condition × time interaction, p = 0.012) and monoester supplementation (Study 2: condition × time interaction, p = 0.016) compared to placebo.
PMID 30912285 · one of two readings recorded this
caspase-1 activation
increases, p = 0.016, n = 18
monoester supplementation (Study 2: condition × time interaction, p = 0.016) compared to placebo
PMID 30912285 · one of two readings recorded this
caspase-1 activation
increases, p = 0.012, n = 10
Caspase-1 activation increases after ketone salt (Study 1: condition × time interaction, p = 0.012)
PMID 30912285 · one of two readings recorded this
IL-1β secretion
increases, p = 0.024, n = 18
IL-1β secretion increases (main effect of condition, p = 0.024; Study 2)
PMID 30912285 · one of two readings recorded this
IL-1beta secretion from LPS-stimulated whole blood after ketone supplementation, ex vivo
increases, p = 0.024
Not recorded as a finding: Stated for Study 2 (ketone monoester) only, which is not this subject; no node for stimulated IL-1beta
IL-1β secretion increases (main effect of condition, p = 0.024; Study 2) while IL1B and NLRP3 mRNA remain unchanged.
PMID 30912285 · one of two readings recorded this
IL1B mRNA
no effect
IL-1β secretion increases (main effect of condition, p = 0.024; Study 2) while IL1B and NLRP3 mRNA remain unchanged
PMID 30912285 · one of two readings recorded this
NLRP3 mRNA
no effect
IL-1β secretion increases (main effect of condition, p = 0.024; Study 2) while IL1B and NLRP3 mRNA remain unchanged
PMID 30912285 · one of two readings recorded this
gastrointestinal symptom load, 0-8 Likert symptom severity, ketone salt drinks at high versus low dose and versus ketone monoester
increases, 13.8 ± 4.3 vs. 2.0 ± 1.0
Not recorded as a finding: the comparison was against another active treatment
High-dose KS drinks caused greater total-visit symptom load than low-dose KS drinks (13.8 ± 4.3 vs. 2.0 ± 1.0; p < .05) and significantly greater time-point symptom load than KME drinks 1-2 hr postdrink.
PMID 31034254 · one of two readings recorded this
gastrointestinal symptom load, symptom type and severity rated 0 to 8 on a Likert scale
increases, 13.8 ± 4.3 vs. 2.0 ± 1.0 (high-dose vs low-dose ketone salt)
Not recorded as a finding: the comparison was against another active treatment
High-dose KS drinks caused greater total-visit symptom load than low-dose KS drinks (13.8 ± 4.3 vs. 2.0 ± 1.0; p < .05) and significantly greater time-point symptom load than KME drinks 1-2 hr postdrink.
PMID 31034254 · one of two readings recorded this
Total-visit gastrointestinal symptom load
no effect
However, during exercise, there was no significant difference in total-visit symptom load between KME+CHO (4.2 ± 1.0) and CHO (7.2 ± 1.9) drinks
PMID 31034254 · one of two readings recorded this
Total-visit gastrointestinal symptom load
increases, p = 0.05
At rest, KME drinks caused greater total-visit symptom load than CHO drinks (5.0 ± 1.6 vs. 0.6 ± 0.4; p < .05)
PMID 31034254 · one of two readings recorded this
Total-visit gastrointestinal symptom load
increases, p = 0.05
High-dose KS drinks caused greater total-visit symptom load than low-dose KS drinks (13.8 ± 4.3 vs. 2.0 ± 1.0; p < .05)
PMID 31034254 · one of two readings recorded this
Visits with no symptoms reported after ketone drinks
n = 60
The number of visits with no symptoms reported after ketone drinks was n = 32/60 in Study 1, n = 9/32 in Study 2, and n = 20/42 in Study 3
PMID 31034254 · one of two readings recorded this
Visits with no symptoms reported after ketone drinks
n = 32
The number of visits with no symptoms reported after ketone drinks was n = 32/60 in Study 1, n = 9/32 in Study 2, and n = 20/42 in Study 3
PMID 31034254 · one of two readings recorded this
Visits with no symptoms reported after ketone drinks
n = 42
The number of visits with no symptoms reported after ketone drinks was n = 32/60 in Study 1, n = 9/32 in Study 2, and n = 20/42 in Study 3
PMID 31034254 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.0001
baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.0001
baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.0001
baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.001
baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus baseline
increases, p = 0.0001
baseline (p < 0.001 for KS; p < 0.0001 for KE, KSMCT, KEKS and KEMCT) levels
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0001
compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0001
compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.0001
compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.01
compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate versus control
increases, p = 0.001
compared to both control (SD; p < 0.01 for KS; p < 0.001 for KSMCT; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate
increases
KE (group 2) | 0.79 ± 0.029 | 1.76 ± 0.087 | ****/14.550 | ****/13.610
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate
increases
KEKS (group 5) | 0.83 ± 0.041 | 1.55 ± 0.073 | ****/11.340 | ****/10.400
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate
increases
KEMCT (group 6) | 0.80 ± 0.033 | 2.14 ± 0.172 | ****/20.230 | ****/19.280
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate
increases
KS (group 3) | 0.83 ± 0.031 | 1.25 ± 0.033 | ***/6.805 | **/5.860
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate
increases
KSMCT (group 4) | 0.81 ± 0.023 | 1.33 ± 0.049 | ****/7.939 | ***/6.994
PMID 32000673 · one of two readings recorded this
blood beta-hydroxybutyrate
no effect
SD (control; group 1) | 0.80 ± 0.037 | 0.86 ± 0.018 | −/0.945 | –
PMID 32000673 · one of two readings recorded this
blood glucose and body weight change after treatment
no effect
After the 7th treatment day, changes in glucose levels and body weight of animals were not detected
PMID 32000673 · one of two readings recorded this
blood glucose
no effect
KE (group 2) | 91.50 ± 2.284 | 97.63 ± 4.342 | −/2.386 | −/0.623
PMID 32000673 · one of two readings recorded this
blood glucose
no effect
KEKS (group 5) | 86.38 ± 2.398 | 92.13 ± 3.388 | −/0.865 | −/0.899
PMID 32000673 · one of two readings recorded this
blood glucose
no effect
KEMCT (group 6) | 85.00 ± 2.659 | 80.88 ± 4.286 | −/2.248 | −/4.011
PMID 32000673 · one of two readings recorded this
blood glucose
no effect
KS (group 3) | 88.38 ± 1.772 | 100.13 ± 5.482 | −/3.078 | −/1.314
PMID 32000673 · one of two readings recorded this
blood glucose
no effect
KSMCT (group 4) | 83.63 ± 3.600 | 97.00 ± 5.745 | −/2.213 | −/0.449
PMID 32000673 · one of two readings recorded this
blood glucose
no effect
SD (control; group 1) | 89.00 ± 1.937 | 95.38 ± 2.672 | −/1.764 | –
PMID 32000673 · one of two readings recorded this
body weight
no effect
KE (group 2) | 331.9 ± 2.496 | 324.9 ± 2.608 | −/0.027
PMID 32000673 · one of two readings recorded this
body weight
no effect
KEKS (group 5) | 316.9 ± 5.377 | 306.6 ± 6.434 | −/3.986
PMID 32000673 · one of two readings recorded this
body weight
no effect
KEMCT (group 6) | 321.8 ± 5.502 | 316.8 ± 5.640 | −/1.790
PMID 32000673 · one of two readings recorded this
body weight
no effect
KS (group 3) | 323.1 ± 2.394 | 313.5 ± 3.942 | −/2.495
PMID 32000673 · one of two readings recorded this
body weight
no effect
KSMCT (group 4) | 318.0 ± 5.119 | 314.0 ± 5.719 | −/2.386
PMID 32000673 · one of two readings recorded this
body weight
no effect
SD (control, group 1) | 325.0 ± 3.134 | 331.8 ± 4.427 | −/1.464
PMID 32000673 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases
or the group means were considered (R2 = 0.5553)
PMID 32000673 · one of two readings recorded this
correlation of latency to immobility with blood beta-hydroxybutyrate
increases
when individual data points (R2 = 0.2933)
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
no effect
DPCPX (group 7) | 146.25 ± 4.443 | −/0.765
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
increases
KE (group 2) | 173.50 ± 3.105 | ****/10.220
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
increases
KEKS (group 5) | 183.88 ± 4.299 | ****/13.680
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
increases
KEMCT (group 6) | 171.75 ± 2.226 | ****/9.634
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
increases
KS (group 3) | 162.50 ± 1.679 | ***/6.548
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
increases
KSMCT (group 4) | 157.88 ± 3.446 | */5.005
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
no effect
SCH 58261 (group 8) | 141.63 ± 4.935 | −/0.283
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
no effect
KEKS + DPCPX (group 9) | 138.13 ± 4.202 | −/1.177
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
increases
KEKS + SCH 58261 (group 10) | 187.13 ± 5.531 | ****/12.290
PMID 32000673 · one of two readings recorded this
latency to immobility under isoflurane
SD (control, group 1) | 142.88 ± 2.474 | –
PMID 32000673 · one of two readings recorded this
latency to immobility versus control
increases, p = 0.0001
compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
latency to immobility versus control
increases, p = 0.0001
compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
latency to immobility versus control
increases, p = 0.0001
compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
latency to immobility versus control
increases, p = 0.001
compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
latency to immobility versus control
increases, p = 0.05
compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT)
PMID 32000673 · one of two readings recorded this
latency to immobility versus control
increases, p = 0.0001
both the rate of this increase and its significance level (p < 0.0001)
PMID 32000673 · one of two readings recorded this
latency to isoflurane-induced immobility, seconds from chamber closure
increases, p < 0.001 for KS against control
Not recorded as a finding: no outcome node for anaesthetic induction latency
Treatments by all exogenous ketone supplements (KE, KS, KSMCT, KEKS and KEMCT; group 2–6) caused a significant increase in the number of seconds required before anesthetic induction (the time until immobility), compared to control (SD; p < 0.05 for KSMCT; p < 0.001 for KS; p < 0.0001 for KE, KEKS and KEMCT) (Table 3) on the 7th day of treatment.
PMID 32000673 · one of two readings recorded this
acute blood ketone response to a single dose, post-treatment
increases, p = 0.001
Post-Treatment = +0.4 ± 0.4 mmol/L; p < 0.001
PMID 33111587 · one of two readings recorded this
acute blood ketone response to a single dose, pre-treatment
increases, p = 0.001
Pretreatment = +0.4 ± 0.3 mmol/L; p < 0.001
PMID 33111587 · one of two readings recorded this
acute blood ketone response to a single dose
no effect
At pre- and post-treatment, CON showed no acute changes in blood ketones after a single-dosing
PMID 33111587 · one of two readings recorded this
acute single-dose blood ketone response, pre versus post treatment
no effect
These acute single-dosing responses in blood ketone levels for KET did not change between pre- and post-treatment
PMID 33111587 · one of two readings recorded this
average time-to-completion of two 800 m time trials (TTAVG)
no effect
KET demonstrated a faster TTAVG from pre- to post-treatment (-6.1 ± 8.9 s; p = 0.02) while CON showed no change
PMID 33111587 · one of two readings recorded this